Seven-membered heterocyclic [1,2,5]triazepane and [1,2,5]-oxadiazepane derivatives were synthesized as candidate structures for application in drug discovery in place of conventional piperazine or morpholine moieties, offering multiple sites for modification with functional groups. We first synthesized the Nprotected heterocycles, and then confirmed their utility by synthesizing analogues of the oxazolidinone antibacterial agent linezolid. The analogues exhibited potent in vitro and in vivo antibacterial activity. In particular, compound 10a exhibited good in vivo efficacy when administered intravenously in a murine model of systemic infection with methicillin-resistant Staphylococcus aureus SR3637. These seven-membered heterocycles are expected to be versatile structural units for drug discovery.
Pharmacologically active low-molecular organic compounds generally consist of a core structural unit, known as the pharmacophore, linked to appropriate functional group(s). Six-membered saturated heterocycles represented by piperazine or morpholine have been widely applied as functional or linker units to develop antihistamines, 1, 2) antipsychotics, 3, 4) and antibacterial agents. 5, 6) Two examples are shown in Fig. 1 . 7, 8) In particular, the piperazine ring is found in the structures of various pharmacologically active compounds as a linker or terminal structural unit. Piperazine has two N atoms that can be readily functionalized and can be used to improve both lipophilicity 9) and hydrophilicity, 10) which in turn can improve bioavailability 11) and pharmaceutical formulation properties. 12) We thought that the seven-membered heterocycles [1, 2, 5] triazepane and [1, 2, 5] oxadiazepane, which could be considered homologues of piperazine, might be similarly useful (Fig. 2) . Since [1, 2, 5] triazepane contains three N atoms, a wide range of chemical modifications should be available. Only a few monocyclic [1, 2, 5] triazepane-type compounds have been synthesized so far, 13) and no [1, 2, 5] oxadiazepane derivatives have been reported. Accordingly, we set out to synthesize several N-protected derivatives and to examine whether they might be useful in medicinal chemistry.
First, we attempted to synthesize [1, 2, 5] triazepane and [1,2,5]oxadiazepane frameworks bearing t-butoxycarbonyl (Boc) protective groups. As shown in Chart 1, cyclization precursors, di-protected hydrazine 1a 14) and bis(2-chloroethyl)carbamic acid benzyl ester, 15) were treated with NaH in N,N-dimethylformamide (DMF) to afford all N-protected [1,2,5]triazepane 2a in good yield, followed by catalytic hydrogenation to obtain 3a protected with a Boc group at the 1-position. The bulky Boc group at the 1-position is expected to decrease the basicity and nucleophilicity of the 2-position relative to the 5-position. As expected, selective arylation under basic conditions proceeded at the 5-position to afford nitrobenzene 4a, and catalytic hydrogenation of 4a provided aniline 5a without cleavage of the N-N bond of the [1, 2, 5] triazepane framework. Compound 5a should be a useful building block for N-aryl-type compounds. The [1, 2, 5] oxadiazepane derivative 5b were similarly synthesized from commercially available 1b. 16) The triazepane protected with Boc groups at the 1-and 5-positions (7) was also synthesized via a similar procedure starting from 1a and bis(2-chloroethyl)carbamic acid t-butyl ester (Chart 2). 17) This compound is also expected to be a versatile intermediate. For example, Pd-catalyzed N-arylation 18, 19) of compound 3a yielded a mixture of 2,5-diarylated compound 8a, 5-arylated 8b, and 2-arylated 8c. However, arylation of compound 7 under the same conditions afforded 2-arylated compound 9 in good yield (Chart 3).
We next examined the potential of the new compounds for drug development. Oxazolidione antibacterial agents, 20) represented by linezolid 21) and eperezolid, 22) are a new class of antibacterial reagents effective against methicillin-resistant Staphylococcus aureus (MRSA) 23) or vancomycin-resistant Enterococcus faecium (VRE). 24) Since these compounds contain a six-membered saturated heterocycle (morpholine or piperazine), we examined the effect of replacing these rings with [1, 2, 5] triazepane and [1, 2, 5] oxadiazepane. The target compounds were synthesized from 3a and 3b via similar routes to those reported for the original compounds, respectively. 22, 25) The new compounds 10a 26) and 10b 27) showed excellent in vitro antibacterial activity against MRSA or line- 28) in comparison with linezolid (Table 1) . Furthermore, compound 10a exhibited good in vivo efficacy when administered intravenously in a murine model of systemic infection, with MRSA SR3637 as the infectious organism. 29) Thus, [1, 2, 5] triazepane and [1,2,5]oxadiazepane appear to have great potential as structural units for drug development.
In summary, we synthesized seven-membered saturated heterocyclic [1, 2, 5] triazepane and [1,2,5]oxadiazepane derivatives as candidates for linker or terminal structural moieties for drug development. Introduction of these structures into oxazolidinone antibiotics in place of the original morpholine or piperazine moieties yielded novel active compounds. We consider that these heterocycles have great potential for structural variation and functionalization in drug development studies. 
